Researchers have reported that a new experimental drug for Alzheimer’s disease, donanemab, can moderately slow the progression of the disease by about four to seven months. Eli Lilly and Co. is currently seeking approval from the Food and Drug Administration for donanemab, which would make it the second Alzheimer’s treatment proven to delay the disease …
The Food and Drug Administration (FDA) has granted full approval to Leqembi, marking a significant milestone in the treatment of Alzheimer’s disease. This development is being hailed as the start of a new era for Alzheimer’s patients, although questions remain regarding the drug’s safety, cost, efficacy, and accessibility. Here are five key points to consider: …
Researchers in Alberta have developed a machine-learning model which identifies audio cues suggesting early onset of Alzheimer’s disease and other forms of dementia. The technology listens for specific speech patterns such as longer pauses, word length or complexity, and speech intelligibility, allowing researchers to distinguish between patients and healthy individuals with an accuracy rate of …